Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of Functional Electrical Stimulation on Spasticity, Quadriceps Muscle Strength and Functional Mobility in Individuals With Paraplegia (FES-PAR-RCT)

15 mai 2026 mis à jour par: salih tan, Istanbul Medipol University Hospital

Effects of Functional Electrical Stimulation on Spasticity, Quadriceps Muscle Strength and Functional Mobility in Individuals With Paraplegia: A Randomized Controlled Trial

Spinal cord injury (SCI)-related paraplegia is a complex neurological condition characterized by motor impairment, increased spasticity, and significant functional limitations in daily activities. Spasticity is one of the most common secondary complications after upper motor neuron lesions and can negatively affect rehabilitation outcomes, gait ability, and functional independence.

This randomized controlled study aims to investigate the effects of Functional Electrical Stimulation (FES) applied to the quadriceps muscle in individuals with paraplegia. Participants will be randomly assigned to either a control group receiving conventional neurorehabilitation or an intervention group receiving additional FES treatment.

The primary outcomes include changes in spasticity level, quadriceps muscle strength, and functional mobility. Spasticity will be assessed using the Modified Ashworth Scale (MAS), muscle strength will be evaluated with Manual Muscle Testing (MMT), and functional mobility will be measured using the Spinal Cord Independence Measure (SCIM), Timed Up and Go Test (TUG), and 6-Minute Walk Test (6MWT).

The intervention period will last 8 weeks, with standardized rehabilitation programs applied to both groups. The FES group will additionally receive quadriceps stimulation with specific neuromuscular electrical stimulation parameters.

The findings of this study are expected to provide evidence regarding the effectiveness of FES as an adjunct to conventional rehabilitation in improving motor function and functional independence in individuals with paraplegia.

Aperçu de l'étude

Description détaillée

Spinal cord injury (SCI) is a major cause of long-term disability worldwide, often resulting in paraplegia when the thoracic, lumbar, or sacral spinal segments are affected. Individuals with paraplegia commonly experience significant impairments in voluntary motor control, muscle weakness, spasticity, and reduced functional mobility, all of which contribute to decreased independence in activities of daily living.

Spasticity, defined as a velocity-dependent increase in muscle tone due to hyperexcitability of the stretch reflex, is one of the most frequent complications following upper motor neuron lesions. Although spasticity may occasionally contribute to functional stability, excessive spasticity often interferes with voluntary movement, gait training, and rehabilitation outcomes (Pandyan et al., 2005).

Functional Electrical Stimulation (FES) is a neurorehabilitation technique that delivers electrical impulses to peripheral nerves to evoke functional muscle contractions. It facilitates neuromuscular re-education, enhances motor unit recruitment, and may promote neuroplasticity in the central nervous system. Previous studies have demonstrated that FES can improve muscle strength, walking ability, and functional independence in individuals with neurological impairments (Sheffler & Chae, 2007; Kesar et al., 2010; Hesse et al., 2003).

This study is designed as a prospective, single-center, parallel-group, randomized controlled trial conducted in accordance with CONSORT 2010 guidelines. A total of 60 participants with paraplegia secondary to spinal cord injury will be enrolled and randomly allocated into two groups:

Control Group: Standard neurorehabilitation program only Intervention Group: Standard neurorehabilitation program + FES applied to the quadriceps femoris muscle The rehabilitation program will be conducted 3 days per week for 8 weeks and will include stretching exercises, strengthening exercises, balance training, and transfer training. In the intervention group, FES will be applied 5 days per week for 8 weeks with the following parameters: 35 Hz frequency, 300 µs pulse duration, and 10 seconds on / 20 seconds off cycle.

Outcome assessments will be performed at baseline (week 0) and after intervention (week 8). Spasticity will be evaluated using the Modified Ashworth Scale (MAS), which is widely used in clinical practice for assessing muscle tone in neurological conditions. Quadriceps muscle strength will be measured using Manual Muscle Testing (MMT) based on the Medical Research Council (MRC) scale. Functional mobility and independence will be assessed using SCIM, TUG, and 6MWT.

SCIM is a validated scale specifically developed for individuals with spinal cord injury and assesses self-care, respiration and sphincter management, and mobility domains. TUG test provides an objective measure of functional mobility and fall risk, while 6MWT evaluates functional exercise capacity and endurance.

The primary hypothesis of this study is that FES combined with conventional rehabilitation will significantly reduce spasticity, improve quadriceps muscle strength, and enhance functional mobility compared to conventional rehabilitation alone.

The results of this study are expected to contribute to the evidence base regarding the clinical effectiveness of FES in neurorehabilitation and may support its integration into standard rehabilitation protocols for individuals with paraplegia.

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Mehmet Salih TAN, Doctorate
  • Numéro de téléphone: +905467266876
  • E-mail: mstan@medipol.edu.tr

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Participants will be included in the study if they meet all of the following criteria:
  • Aged between 18 and 65 years
  • Diagnosed with spinal cord injury resulting in paraplegia (traumatic or non-traumatic etiology)
  • Classified as ASIA Impairment Scale C or D
  • Medically stable condition
  • Presence of lower extremity spasticity (Modified Ashworth Scale ≥ 1)
  • Ability to understand and follow simple instructions
  • Willingness to participate and provide informed consent

Exclusion Criteria:

  • Participants will be excluded if they present any of the following conditions:
  • Presence of cardiac pacemaker or implanted electrical device
  • Severe cognitive impairment or communication difficulties preventing participation
  • Active infection or systemic inflammatory condition
  • Severe lower extremity contractures or deformities limiting movement
  • Dermatological conditions or open wounds preventing FES application
  • History of severe autonomic dysreflexia triggered by electrical stimulation
  • Uncontrolled medical conditions that may interfere with participation or safety

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Control Group - Conventional Rehabilitation
Participants in this arm will receive a standard neurorehabilitation program for paraplegia secondary to spinal cord injury. The program will include stretching exercises, progressive strengthening exercises, balance training, and transfer training. Sessions will be conducted 3 days per week, 45-60 minutes per session, for a total duration of 8 weeks. No Functional Electrical Stimulation (FES) will be applied in this group.
This intervention consists of a conventional neurorehabilitation program designed for individuals with paraplegia secondary to spinal cord injury. The program includes stretching exercises, progressive strengthening exercises, balance training, and transfer training. Sessions are conducted 3 days per week, 45-60 minutes per session, over a total duration of 8 weeks. This group does not receive Functional Electrical Stimulation (FES). The intervention is aimed at improving general motor function, maintaining joint range of motion, and enhancing functional independence.
Expérimental: FES + Conventional Rehabilitation Group
Participants in this arm will receive the same standard neurorehabilitation program as the control group, including stretching, strengthening, balance, and transfer training (3 days per week, 45-60 minutes per session for 8 weeks). In addition, Functional Electrical Stimulation (FES) will be applied to the quadriceps femoris muscle. FES parameters will include 35 Hz frequency, 300 µs pulse duration, and a 10-second on / 20-second off cycle. FES will be administered 5 days per week for 8 weeks to facilitate neuromuscular activation, improve muscle strength, and reduce spasticity.
This intervention consists of Functional Electrical Stimulation (FES) applied to the quadriceps femoris muscle in addition to the same conventional neurorehabilitation program provided to the control group. FES is delivered using a neuromuscular electrical stimulation device to induce muscle contractions via peripheral nerve activation. Stimulation parameters include 35 Hz frequency, 300 µs pulse duration, and a 10-second on / 20-second off cycle. The intervention is applied 5 days per week for 8 weeks. The aim is to enhance neuromuscular activation, reduce spasticity, increase quadriceps muscle strength, and improve functional mobility in individuals with paraplegia.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Spasticity Level
Délai: Baseline and Week 8
Spasticity will be assessed using the Modified Ashworth Scale (MAS), which grades muscle tone from 0 to 4. Higher scores indicate increased spasticity. The primary comparison will be the change in MAS scores between baseline and after 8 weeks of intervention.
Baseline and Week 8
Quadriceps Muscle Strength
Délai: Baseline and Week 8
Muscle strength will be evaluated using Manual Muscle Testing (MMT) based on the Medical Research Council (MRC) scale (0-5). Higher scores indicate greater muscle strength.
Baseline and Week 8
Functional Mobility
Délai: Baseline and Week 8

Functional mobility will be assessed using:

Spinal Cord Independence Measure (SCIM) Timed Up and Go Test (TUG) 6-Minute Walk Test (6MWT) SCIM evaluates independence in daily activities, TUG assesses functional mobility and fall risk, and 6MWT measures walking capacity and endurance. Improvements indicate better functional mobility.

Baseline and Week 8

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Functional Independence (SCIM subdomains)
Délai: Baseline and Week 8
Changes in self-care, respiration/sphincter management, and mobility domains of SCIM will be analyzed separately.
Baseline and Week 8
Walking Performance
Délai: Baseline and Week 8
Total distance walked in 6 minutes (meters). Increased distance indicates improved functional endurance
Baseline and Week 8
Functional Mobility Performance
Délai: Baseline and Week 8
Time required (seconds) to stand up, walk 3 meters, turn, return, and sit down. Lower time indicates improved mobility.
Baseline and Week 8
Spasticity Severity
Délai: Baseline and Week 8
Comparison of spasticity reduction between intervention and control groups.
Baseline and Week 8

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

10 mai 2026

Achèvement primaire (Estimé)

10 juin 2026

Achèvement de l'étude (Estimé)

10 juillet 2026

Dates d'inscription aux études

Première soumission

3 mai 2026

Première soumission répondant aux critères de contrôle qualité

8 mai 2026

Première publication (Réel)

13 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The fully anonymized individual participant data (IPD) obtained in this study will be shared with appropriate researchers upon reasonable request following the publication of primary results. Data sharing will be carried out in accordance with institutional ethics committee regulations and applicable data protection laws.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner